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The process of hair cell damage and death as a result of exposure to noise and ototoxins seems 
to be mediated by reactive oxygen species. 
Aim: To investigate the relationship between genetic polymorphisms in the Glutathione S-transferase 
and the susceptibility to hearing loss induced by aminoglycosides. 
Materials and Methods: Null genotypes were analyzed by multiplex-PCR in the DNA samples from 
50 patients and 72 controls. The patients were divided into 3 groups, 10 with hearing loss using 
aminoglycosides (group A), 20 with hearing loss without exposure to the drug (group B) and 20 
hearing individuals who used the antibiotic (group C). 
Study Design: Experimental. 
Results: Polymorphisms in the GSTM1 and GSTT1 genes were found in 16% and 42% of patients and 
in 18% and 53% of the control group, respectively. After statistical analysis no significant difference 
was observed between the control groups and A (p=0.86) and (p=0.41), controls and B (p=0.27) 
and (p=0.24), controls and C (p=0.07) and (p=0.47), controls and A + C (p=0.09) and (p=0.47), C 
and A (p=0.32) and (p=0.75), GSTT1 and GSTM1, respectively. 
Conclusion: Our data show that polymorphisms in GSTM1 and GSTT1 genes have no influence 
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INTRODUCTION
Many are the factors responsible for hearing impair-
ment (HI), and they include the environment, infections, 
noise and ototoxic agents - which damage the auditory 
nerve; or genetics1. Among the genetic cases, it is believed 
that there are more than 100 genes involved in the etiology 
of non-syndromic sensorineural hearing loss2.
Oxygen reactive species (ORS) are involved in a 
growing number of diseases, including hearing loss - in a 
lesser frequency. Nonetheless, oxidative stress is strongly 
related to ototoxic-induced hearing deficiency caused by 
aminoglycosides or the noise-induced hearing loss type. 
In these cases, the toxic components are converted into 
hydroxyl radicals, causing the death of cochlear hair cells3. 
Nonetheless, in normal metabolic processes, important 
ORS (superoxide anions, hydrogen peroxide and hydroxyl 





Thus, enzymes belonging to the antioxidant system, which 
act on the metabolism of glutathione and on the decom-
position of superoxide anions and hydrogen peroxide, 
are activated on an attempt to neutralize these molecules 
which potentially damage the cochlear tissue4.
Glutathione (GSH) detoxifies a number of exoge-
nous and endogenous substances, by a non-enzymatic 
pathway and by enzymatic conjugation of the metabolites 
catalyzed by S-Transferase Glutathione (GST)5. GSTs are 
broken down into eight gene classes which codify cytoso-
lic enzymes and microsomal genes: α (GSTA), μ (GSTM), 
π (GSTP), θ (GSTT), z (GSTZ), σ (GSTS), w (GSTO) and 
k (GSTK)6. The GST enzymes have different affinities to 
numerous substrates and are found in many tissues at 
different concentrations7.
In humans, two of these subclasses GSTM1 and 
GSTT1, have genetic variability. About 30-50% of the indi-
viduals had a null genotype for gene GSTM1, depending 
on the race8 and 25-40% carried the null genotype of gene 
GSTT19. Individuals with the null genotype do not conju-
gate metabolites or specific toxins for these enzymes, thus 
increasing susceptibility to damage caused by oxidative 
stress and, possibly, the noise-induced hearing deficit10.
Changes to the antioxidant system and an increase 
in the oxidative stress can potentialize the toxicological 
responses associated with glutathione reduction. This 
indicates that the radicals generated modulate the activity 
and the expression of the antioxidant enzymes11. In the 
cochlea, the antioxidant activities play a crucial role on 
the reduction of damage caused by ototoxic agents, noise 
and aging. In vitro, gentamicin forms a complex with iron, 
producing free radicals12. Similarly, in vivo, it increases 
the levels of peroxide in the lipids13. In an external hair 
cell culture, glutathione prevents gentamicin-induced 
cytotoxicity and dampens the antibiotic-induced hearing 
loss in malnourished animals14. Thus, this study aimed 
at assessing the genetic variability of genes GSTM1 and 
GSTT1 and the ototoxic susceptibility of the aminoglyco-




The study was carried out in individuals with hearing 
impairment (HI) who used or did not use aminoglycoside 
ototoxic antibiotics, and in hearing newborns, premature 
and high-risk babies who remained at least 48 hours in 
the neonatal ICU and were exposed to the antibiotic. The 
patients were broken down into three groups: group A, 
individuals with hearing impairment and who used amino-
glycosides (n=10); group B, with hearing impairment and 
who did not use aminoglycosides (n=20); and group C, 
hearing individuals who used aminoglycosides (n=20). The 
control group was made up of 72 individuals, randomly 
selected from the general population.
Molecular analysis of genes GSTM1 and GSTT1
Samples of genomic DNA were extracted from the 
peripheral blood after obtaining the signed consent form 
approved by the Ethics Committee (Approval # 484/2006). 
In order to extract the DNA from individuals from the ge-
neral population we used the DNAzol reagent, according 
to instructions from the manufacturer (Invitrogen®). In 
the samples from the other groups we used the phenol-
chloroform standard.
The polymorphic sequences of genes GSTM1 and 
GSTT1 were established by a multiplex PCR, including the 
b-globin gene as internal control of the 630pb15 amplifi-
cation. The reaction was carried out using 200 to 500ng 
of the genomic DNA, 10mM of solution with deoxynucle-
otides (dATP, dCTP, dGTP and dTTP), 20pmol/ml of the 
b-globin gene primers, 10pmol/ml of each primer from 
genes GST; 2.5U of Taq DNA polymerase; 10X PCR buffer 
(Tris-HCl 10mM pH 8.8) and 3mM of MgCl2, in a final 
volume of 50ml. PCR-multiplex conditions happened by 
an initial denaturation at 95°C for 3min followed by 35 
cycles (95°C for 1min; 60°C per 1min; 72°C per 1min) and 
a final extension at 72°C for 10min. The PCR products were 
analyzed in 1.5% agarose gel dyed in ethide bromide, and 
the null genotype (both alleles deleted) for genes GSTT1 
and GSTM1 was identified by the absence of amplification 
fragments of 480pb and 273pb, respectively (Fig.1).
Statistical Analysis
The statistical significance differences between the 
groups were calculated by c2 followed by the Yates cor-
rection with a 5% significance level (p £ 0.05 values are 
considered significant).
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RESULTS
The genotypes were grouped by hearing normality, 
presence of hearing impairment and exposure to amino-
glycoside antibiotics. The null GSTT1 was found in 16% 
(08 of 50) of the patients and in 18% (13 of 72) of the 
control individuals (p= 0.009). Null GSTM1 alleles were 
found in 21 (42%) of the 50 patients studied and in 38 
(53%) individuals from the general population (p= 0.049). 
The frequency of homozygote GSTT1 and GSTM1 geno-
types was significantly lower in patients assessed when 
compared to control individuals.
The frequency of null GSTT1 and GSTM1 genotypes 
and the comparison of the results among the groups are 
shown on Table 1. Nonetheless, no significant statistical 
difference was seen in groups control and A (p= 0.86) and 
(p= 0.41), control and B (p= 0.27) and (p= 0.24), control 
and C (p= 0.07) and (p= 0.47), control and A+C (p= 0.09) 
and (p= 0.47), C and A (p= 0.32) and (p= 0.75), GSTT1 
and GSTM1, respectively.
DISCUSSION
Antioxidant and detoxifying reactions related to 
glutathione are essential for intracellular protection. No-
netheless, it is known that the treatment with some drugs 
and time affect the inner ear defense system of mammals. 
Noise exposure and treatment with gentamicin do not 
affect tissue glutathione levels. Nonetheless, the antioxi-
dant system is being influenced by aging and by the use 
of cisplatin16.
Many studies suggest that the antioxidant activity 
can impact the hearing loss susceptibility. There are reports 
of genetic polymorphism on GSTM1 which act against the 
ototoxicity of cisplatin17, besides showing an apparent 
protective effect on the external hair cells in noise-exposed 
individuals10. In such a case, individuals with null genotype 
for the GSTM1 gene, on the otoacoustic emission, have 
lower amplitude for higher frequencies when compared 
to individuals without polymorphism in this gene. On the 
other hand, in another study, we did not show any evi-
dence that the genetic variability of the antioxidant system 
prevails over other potential factors on the susceptibility 
regarding noise-induced hearing loss18.
Figure 1. Null GSTM1 and GSTT1 genotype detection. Electrophoresis 
in 1.5% agarose gel showing the products of PCR-multiplex of 273bp 
and 480pb, correspondent. Presence of the normal allele of genes 
GSTM1 and GSTT1, respectively. The 630pb fragment represents the 
internal amplification control. (1) - molecular weight marker (100pb); 
(2,3,6) - individuals with normal GSTM1 and GSTT1 alleles, (4) - in-
dividual with a null allele for gene GSTT1, (5) - individuals with null 
combined allele for genes GSTM1 and GSTT1, (7) - individual with 
null allele for gene GSTM1.
Table 1.Null genotypes from genes GSTT1 and GSTM1 in control individuals and in patients with and without exposure to aminoglycosides.
Genotypes* Group A (n=10) Group B (n=20) Group C (n=20) Control (n=72)
n (%) n (%) n (%) n (%)
GSTM1     
Positive [+] 6 (60) 12 (60) 11 (55) 34 (47)
Null [-] 4 (40) 8 (40) 9 (45) 38 (53)
GSTT1     
Positive [+] 8 (80) 17 (85) 13 (65) 59 (82)
Null [-] 2 (20) 3 (15) 7 (35) 13 (18)
Combined GSTM1/ 
GSTT1
    
[-]/[-] 2 (20) 0 (0) 4 (20) 6 (9)
[+]/[+] 6 (60) 9 (45) 8 (40) 27 (37)
[+]/[-] 0 (0) 3 (15) 3 (15) 7 (10)
[-]/[+] 2 (20) 8 (40) 5 (25) 32 (44)
[-]: null genotype; [+]: non-null genotype.
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The availability of information on GSTT1 and 
GSTM1 polymorphisms in the Brazilian population is still 
scarce19. A study carried out in the Brazilian population 
from the states of Pará and São Paulo showed frequencies 
of 18% and 47.3% for the null genotypes for genes GSTT1 
and GSTM1, respectively20. In this paper, the frequencies 
found were very similar, null genotype for GSTT1 was of 
16% and for GSTM1 it was 42%. Notwithstanding, there 
is no data in the literature for glutathione S-transferase 
(GSTT1 and GSTM1) polymorphism be associated to the 
susceptibility of aminoglycoside-induced hearing loss.
Nonetheless, we know that there are numerous 
environmental factors which can cause hearing loss, such 
as glutathione S-transferase that have an important role 
to play on the defense against oxidative stress caused by 
these factors.
CONCLUSION
Our data strongly suggests that the null GSTT1 and 
GSTM1 genotypes are not associated to aminoglycoside-
induced hearing loss.
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